Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial.

Glaucoma, Open-Angle Humans Intraocular Pressure Macula Lutea Ocular Hypertension / drug therapy Prostaglandins F, Synthetic Retinal Vessels Timolol / therapeutic use Tomography, Optical Coherence

Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
09 2022
Historique:
received: 07 01 2022
revised: 30 03 2022
accepted: 26 04 2022
pubmed: 9 5 2022
medline: 9 9 2022
entrez: 8 5 2022
Statut: ppublish

Résumé

To compare the differences in retinal vessel density (VD) between topical administration of latanoprostene bunod (LBN) ophthalmic solution 0.024% and timolol maleate 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) and normal subjects. Randomized, single center, crossover clinical trial. Eligible subjects were examined during 6 study visits over 12 weeks. All subjects were randomized in a 1:1 ratio to LBN dosed once daily or timolol dosed twice daily in both eyes (OU) for a duration of 4 weeks each, separated by a 2-week washout period. A comprehensive eye examination OU was performed at each visit. Testing was performed with optical coherence tomography and optical coherence tomography angiography (optic nerve and macula), as well as visual field examination, on the study eye at baseline and before and after each treatment. One eye from each of 50 patients was enrolled (10 healthy patients, 26 patients with OHT, and 14 patients with OAG). After administration of LBN there was significantly increased macular VD (0.76% [0.20%-1.33%], P = 0.009) and a trend in increasing peripapillary VD in patients with OAG and patients with OHT. In contrast, after administration of timolol, there were no differences in macular VD, and a decrease in peripapillary VD only was observed in the nasal inferior sector (-0.56% [-1.08% to -0.03%], P = .04) in patients with OAG and patients with OHT. No change in peripapillary or macular VD was observed in the normal subjects (P > .05 for all). Topical administration of LBN enhanced macular VD in patients with OAG or patients with OHT. In contrast, timolol administration did not have any effect on VD.

Identifiants

DOI: 10.1016/j.ajo.2022.04.022 PMID: 35526590 PMC: PMC9444916
pubmed: 35526590
pii: S0002-9394(22)00174-X
doi: 10.1016/j.ajo.2022.04.022
pmc: PMC9444916
mid: NIHMS1823984
pii:
doi:

Substances chimiques

BOL 303259-X 0
Prostaglandins F, Synthetic 0
Timolol 817W3C6175

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-129

Subventions

Organisme : NEI NIH HHS
ID : K08 EY033032
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513-8
pubmed: 7732899
Exp Eye Res. 1989 May;48(5):707-16
pubmed: 2737263
Ophthalmology. 1996 Jan;103(1):138-47
pubmed: 8628544
Eur J Ophthalmol. 2002 Jan-Feb;12(1):44-8
pubmed: 11936443
J Pharmacol Exp Ther. 1992 Mar;260(3):956-65
pubmed: 1532035
Am J Ophthalmol. 1980 Jul;90(1):106-9
pubmed: 6772033
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
J Glaucoma. 2020 Nov;29(11):1025-1029
pubmed: 32890106
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
J Ocul Pharmacol Ther. 2003 Dec;19(6):527-34
pubmed: 14733710
Ann Intern Med. 2013 Feb 19;158(4):271-9
pubmed: 23420235
Ophthalmology. 2017 Nov;124(11):1589-1599
pubmed: 28676279
Ophthalmic Res. 1983;15(3):160-7
pubmed: 6314218
BMC Ophthalmol. 2018 Dec 10;18(1):315
pubmed: 30526537
Vestn Oftalmol. 2019;135(4):70-77
pubmed: 31573559
Cell Calcium. 1994 Feb;15(2):122-31
pubmed: 8149412
Can J Ophthalmol. 2008 Jun;43(3):281-3
pubmed: 18504463
Opt Express. 2012 Feb 13;20(4):4710-25
pubmed: 22418228
Curr Eye Res. 1981;1(4):205-9
pubmed: 6949676
Ophthalmol Clin North Am. 2002 Mar;15(1):61-8
pubmed: 12064082
Am J Ophthalmol. 2019 Mar;199:120-132
pubmed: 30496723
Ophthalmology. 2018 Nov;125(11):1720-1728
pubmed: 29907322
Ophthalmology. 2020 Aug;127(8):1043-1052
pubmed: 32085875
Exp Eye Res. 1988 Nov;47(5):761-9
pubmed: 3197775
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4419-26
pubmed: 14507888
Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H631-6
pubmed: 12750062
J Glaucoma. 2021 Jun 1;30(6):e276-e284
pubmed: 33899812
Invest Ophthalmol Vis Sci. 1988 May;29(5):695-9
pubmed: 2835327
Exp Eye Res. 1994 Jan;58(1):99-105
pubmed: 8157106
Br J Ophthalmol. 2023 Jul;107(7):953-958
pubmed: 35101938
Am Heart J. 1980 Aug;100(2):160-78
pubmed: 6105819
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1257-1264
pubmed: 29520478
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Adv Ther. 2004 Jul-Aug;21(4):203-13
pubmed: 15605615
Invest Ophthalmol Vis Sci. 1997 Oct;38(11):2214-23
pubmed: 9344344
Am J Ophthalmol. 2019 Nov;207:99-109
pubmed: 31170389
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Curr Eye Res. 2000 Jun;20(6):511-6
pubmed: 10980664
Ophthalmology. 2016 Jan;123(1):P41-P111
pubmed: 26581556
J Ocul Pharmacol Ther. 1995 Summer;11(2):107-12
pubmed: 8564631
Arch Ophthalmol. 1992 Dec;110(12):1733-8
pubmed: 1463414
Arch Ophthalmol. 2002 Oct;120(10):1268-79
pubmed: 12365904
J Glaucoma. 2021 Aug 1;30(8):690-696
pubmed: 33927152
BMJ Open Ophthalmol. 2017 Jul 11;1(1):e000032
pubmed: 29354699
Prog Retin Eye Res. 2002 Jul;21(4):359-93
pubmed: 12150988

Auteurs

Nevin W El-Nimri (NW)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Sasan Moghimi (S)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Rafaella C Penteado (RC)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Elham Ghahari (E)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Diya Yang (D)

Beijing Tongren Eye Center (D.Y.), Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Nicole Brye (N)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

James Proudfoot (J)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Jiun L Do (JL)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Andrew Camp (A)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Matthew Salcedo (M)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Veronica Rubio (V)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA.

Robert N Weinreb (RN)

From the Hamilton Glaucoma Center (N.W.E., S.M., R.C.P., E.G., N.B., J.P., J.L.D., A.C., M.S., V.R., R.N.W.), Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California, USA. Electronic address: rweinreb@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'oeil › Hypertension oculaire › Glaucome › Glaucome à angle ouvert › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Phénomènes physiologiques oculaires › Pression intraoculaire › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Organes des sens › Oeil › Rétine › Macula › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Maladies de l'oeil › Hypertension oculaire › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Prostaglandines synthétiques › Prostaglandines F synthétiques › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Système cardiovasculaire › Vaisseaux sanguins › Vaisseaux rétiniens › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Oxazines › Morpholines › Timolol › Comparison of the Effects of Latanoprostene...
questionsmedicales.fr › Techniques d'investigation › Imagerie optique › Tomographie optique › Tomographie par cohérence optique › Comparison of the Effects of Latanoprostene...